3 results about "Chemosensitizer" patented technology

The invention relates to an effect of limited uptake of arachidonic acid (AA) in preparation of a chemotherapy sensitizer, and particularly relates to an application of the arachidonic acid (AA) in preparation of the chemotherapy sensitizer. A large number of researches find that the AA content is extremely related to the colorectal cancer chemotherapy resistance, the high level of AA has negative correlation with the colorectal cancer chemotherapy sensitivity, the AA can be used for predicting the colorectal cancer chemotherapy tolerance and sensitivity degree, and early evaluation is provided for the relation of preoperative treatment of a patient. Meanwhile, AA uptake is limited, for example, AA transporter SLC27A4 is inhibited, an important function of colorectal cancer chemotherapy sensitization is achieved, correspondingly, the tolerance of a patient to colorectal cancer chemotherapy can be reduced by reducing the level of AA in a body, the chemotherapy treatment effect is improved, the survival rate of the patient is prolonged, and prognosis is improved. The invention provides sufficient scientific basis and theoretical basis for exploring new colorectal cancer diagnosis, prognosis judgment and treatment molecular targets and developing new targeted drugs, is helpful for better realizing accurate treatment, and has important social value and scientific significance.

The application discloses application of lumacaftor in improving paclitaxel resistance of triple-negative breast cancer, and belongs to the technical field of biological medicine. The application provides application of a drug composition in preparation of a drug for preventing and / or treating paclitaxel-resistant triple-negative breast cancer; and an active ingredient of the drug composition is lumacaftor and paclitaxel. It is found for the first time that lumacaftor can significantly enhance the killing effect of paclitaxel on TNBC drug-resistant cells, and the mechanism may be related to inhibition of glycolysis pathway, recovery of cell cycle arrest and promotion of apoptosis signal. Experimental results prove that, as a GTM1 agonist, lumacaftor can inhibit the AMPK-glycolysis pathway and reduce lactic acid generation; in combination with paclitaxel in paclitaxel-resistant cells, cell proliferation is significantly inhibited, but the effect is not significant in parent cells. Therefore, lumacaftor can be used as a chemosensitizer for paclitaxel-resistant triple-negative breast cancer, and has a clear mechanism and good application prospect.

The present application relates to a kind of isoquinoline alkaloid derivatives for reversing tumor multidrug resistance by inhibiting autophagy and preparation method and application.The derivative can efficiently reverse the multidrug resistance of various solid tumor cells such as gastric cancer, lung cancer and esophageal cancer, the derivative can inhibit the autophagy flow of tumor cells, it is combined with vincristine, mitoxantrone, colchicine, docetaxel and various chemotherapeutic drugs, can efficiently reverse tumor multidrug resistance in vivo and in vitro, this kind of derivative has excellent oral bioavailability and lower toxic side effects, provides a kind of alternative strategy for autophagy inhibitor as antitumor chemosensitizer, can be used as lead compound for the research and development of new drug-resistant tumor reversing agent.